Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Pons-Grífols A"'
Autor:
Carlos Ávila-Nieto, Júlia Vergara-Alert, Pep Amengual-Rigo, Erola Ainsua-Enrich, Marco Brustolin, María Luisa Rodríguez de la Concepción, Núria Pedreño-Lopez, Jordi Rodon, Victor Urrea, Edwards Pradenas, Silvia Marfil, Ester Ballana, Eva Riveira-Muñoz, Mònica Pérez, Núria Roca, Ferran Tarrés-Freixas, Guillermo Cantero, Anna Pons-Grífols, Carla Rovirosa, Carmen Aguilar-Gurrieri, Raquel Ortiz, Ana Barajas, Benjamin Trinité, Rosalba Lepore, Jordana Muñoz-Basagoiti, Daniel Perez-Zsolt, Nuria Izquierdo-Useros, Alfonso Valencia, Julià Blanco, Victor Guallar, Bonaventura Clotet, Joaquim Segalés, Jorge Carrillo
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-18 (2024)
Abstract Safe and effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are crucial to fight against the coronavirus disease 2019 pandemic. Most vaccines are based on a mutated version of the Spike glycoprotein [K986P/V987P
Externí odkaz:
https://doaj.org/article/417894952ca54f88947455ec8d336df7
Autor:
Leire de Campos-Mata, Benjamin Trinité, Andrea Modrego, Sonia Tejedor Vaquero, Edwards Pradenas, Anna Pons-Grífols, Natalia Rodrigo Melero, Diego Carlero, Silvia Marfil, César Santiago, Dàlia Raïch-Regué, María Teresa Bueno-Carrasco, Ferran Tarrés-Freixas, Ferran Abancó, Victor Urrea, Nuria Izquierdo-Useros, Eva Riveira-Muñoz, Ester Ballana, Mónica Pérez, Júlia Vergara-Alert, Joaquim Segalés, Carlo Carolis, Rocío Arranz, Julià Blanco, Giuliana Magri
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-13 (2024)
Abstract Here we report the characterization of 17T2, a SARS-CoV-2 pan-neutralizing human monoclonal antibody isolated from a COVID-19 convalescent individual infected during the first pandemic wave. 17T2 is a class 1 VH1-58/κ3-20 antibody, derived
Externí odkaz:
https://doaj.org/article/e88c94774f434c16bec8caaf30b4258f
Autor:
Ana Barajas, Pep Amengual-Rigo, Anna Pons-Grífols, Raquel Ortiz, Oriol Gracia Carmona, Victor Urrea, Nuria de la Iglesia, Juan Blanco-Heredia, Carla Anjos-Souza, Ismael Varela, Benjamin Trinité, Ferran Tarrés-Freixas, Carla Rovirosa, Rosalba Lepore, Miguel Vázquez, Leticia de Mattos-Arruda, Alfonso Valencia, Bonaventura Clotet, Carmen Aguilar-Gurrieri, Victor Guallar, Jorge Carrillo, Julià Blanco
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-14 (2024)
Abstract Background Neoantigens are patient- and tumor-specific peptides that arise from somatic mutations. They stand as promising targets for personalized therapeutic cancer vaccines. The identification process for neoantigens has evolved with the
Externí odkaz:
https://doaj.org/article/83a923e41a4c4f16982d7a9a094b4b9c
Autor:
Ferran Tarrés-Freixas, Carmen Aguilar-Gurrieri, María Luisa Rodríguez de la Concepción, Victor Urrea, Benjamin Trinité, Raquel Ortiz, Edwards Pradenas, Pau Blanco, Sílvia Marfil, Luis Manuel Molinos-Albert, Ana Barajas, Anna Pons-Grífols, Carlos Ávila-Nieto, Ismael Varela, Laura Cervera, Sònia Gutiérrez-Granados, María Mercedes Segura, Francesc Gòdia, Bonaventura Clotet, Jorge Carrillo, Julià Blanco
Publikováno v:
npj Vaccines, Vol 8, Iss 1, Pp 1-13 (2023)
Abstract Antigen display on the surface of Virus-Like Particles (VLPs) improves immunogenicity compared to soluble proteins. We hypothesised that immune responses can be further improved by increasing the antigen density on the surface of VLPs. In th
Externí odkaz:
https://doaj.org/article/20b68eeb7d6f4ecfa2c0a0005799608d
Autor:
Raquel Ortiz, Ana Barajas, Anna Pons-Grífols, Benjamin Trinité, Ferran Tarrés-Freixas, Carla Rovirosa, Víctor Urrea, Antonio Barreiro, Anna Gonzalez-Tendero, Maria Rovira-Rigau, Maria Cardona, Laura Ferrer, Bonaventura Clotet, Jorge Carrillo, Carmen Aguilar-Gurrieri, Julià Blanco
Publikováno v:
Viruses, Vol 16, Iss 6, p 987 (2024)
The envelope glycoprotein (Env) of retroviruses, such as the Feline leukemia virus (FeLV), is the main target of neutralizing humoral response, and therefore, a promising vaccine candidate, despite its reported poor immunogenicity. The incorporation
Externí odkaz:
https://doaj.org/article/28f6dcb59e8c49f0b75c64e52e01d415
Autor:
Carlos Ávila-Nieto, Júlia Vergara-Alert, Pep Amengual-Rigo, Erola Ainsua-Enrich, Marco Brustolin, María Luisa Rodríguez de la Concepción, Núria Pedreño-Lopez, Jordi Rodon, Victor Urrea, Edwards Pradenas, Silvia Marfil, Ester Ballana, Eva Riveira-Muñoz, Mònica Pérez, Núria Roca, Ferran Tarrés-Freixas, Julieta Carabelli, Guillermo Cantero, Anna Pons-Grífols, Carla Rovirosa, Carmen Aguilar-Gurrieri, Raquel Ortiz, Ana Barajas, Benjamin Trinité, Rosalba Lepore, Jordana Muñoz-Basagoiti, Daniel Perez-Zsolt, Nuria Izquierdo-Useros, Alfonso Valencia, Julià Blanco, Bonaventura Clotet, Victor Guallar, Joaquim Segalés, Jorge Carrillo
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Most COVID-19 vaccines are based on the SARS-CoV-2 Spike glycoprotein (S) or their subunits. However, S shows some structural instability that limits its immunogenicity and production, hampering the development of recombinant S-based vaccines. The in
Externí odkaz:
https://doaj.org/article/8d145e1f4f964517b358c973214ef36f
Autor:
Pradenas, Edwards, Marfil, Silvia, Urrea, Víctor, Trigueros, Macedonia, Pidkova, Tetyana, Pons-Grífols, Anna, Ortiz, Raquel, Rovirosa, Carla, Tarrés-Freixas, Ferran, Aguilar-Gurrieri, Carmen, Toledo, Ruth, Chamorro, Anna, Noguera-Julian, Marc, Mateu, Lourdes, Blanco, Ignacio, Grau, Eulàlia, Massanella, Marta, Carrillo, Jorge, Clotet, Bonaventura, Trinité, Benjamin, Blanco, Julià
Publikováno v:
In iScience 21 April 2023 26(4)
Autor:
Edwards Pradenas, Silvia Marfil, Víctor Urrea, Macedonia Trigueros, Tetyana Pidkova, Anna Pons-Grífols, Raquel Ortiz, Carla Rovirosa, Ferran Tarrés-Freixas, Carmen Aguilar-Gurrieri, Ruth Toledo, Anna Chamorro, Marc Noguera-Julian, Lourdes Mateu, Ignacio Blanco, Eulàlia Grau, Marta Massanella, Jorge Carrillo, Bonaventura Clotet, Benjamin Trinité, Julià Blanco
Publikováno v:
iScience, Vol 26, Iss 4, Pp 106457- (2023)
Summary: The elicitation of cross-variant neutralizing antibodies against SARS-CoV-2 represents a major goal for current COVID-19 vaccine strategies. Additionally, natural infection may also contribute to broaden neutralizing responses. To assess the
Externí odkaz:
https://doaj.org/article/ed779693fcf8488dabf045c750cc1a87
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.